Literature DB >> 22639787

Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies.

Amol Prakash1, Taha Rezai, Bryan Krastins, David Sarracino, Michael Athanas, Paul Russo, Hui Zhang, Yuan Tian, Yan Li, Vathany Kulasingam, Andrei Drabovich, Christopher R Smith, Ihor Batruch, Paul E Oran, Claudia Fredolini, Alessandra Luchini, Lance Liotta, Emanuel Petricoin, Eleftherios P Diamandis, Daniel W Chan, Randall Nelson, Mary F Lopez.   

Abstract

Over the past few years, mass spectrometry has emerged as a technology to complement and potentially replace standard immunoassays in routine clinical core laboratories. Application of mass spectrometry to protein and peptide measurement can provide advantages including high sensitivity, the ability to multiplex analytes, and high specificity at the amino acid sequence level. In our previous study, we demonstrated excellent reproducibility of mass spectrometry-selective reaction monitoring (MS-SRM) assays when applying standardized standard operating procedures (SOPs) to measure synthetic peptides in a complex sample, as lack of reproducibility has been a frequent criticism leveled at the use of mass spectrometers in the clinical laboratory compared to immunoassays. Furthermore, an important caveat of SRM-based assays for proteins is that many low-abundance analytes require some type of enrichment before detection with MS. This adds a level of complexity to the procedure and the potential for irreproducibility increases, especially across different laboratories with different operators. The purpose of this study was to test the interlaboratory reproducibility of SRM assays with various upfront enrichment strategies and different types of clinical samples (representing real-world body fluids commonly encountered in routine clinical laboratories). Three different, previously published enrichment strategies for low-abundance analytes and a no-enrichment strategy for high-abundance analytes were tested across four different laboratories using different liquid chromatography-SRM (LC-SRM) platforms and previously developed SOPs. The results demonstrated that these assays were indeed reproducible with coefficients of variation of less than 30% for the measurement of important clinical proteins across all four laboratories in real world samples.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22639787      PMCID: PMC3761372          DOI: 10.1021/pr300014s

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  45 in total

1.  Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester Trisomy 21 maternal serum.

Authors:  Mary F Lopez; Ramesh Kuppusamy; David A Sarracino; Amol Prakash; Michael Athanas; Bryan Krastins; Taha Rezai; Jennifer N Sutton; Scott Peterman; Kypros Nicolaides
Journal:  J Proteome Res       Date:  2010-06-04       Impact factor: 4.466

Review 2.  Proteomics technologies for the global identification and quantification of proteins.

Authors:  Ian A Brewis; P Brennan
Journal:  Adv Protein Chem Struct Biol       Date:  2010       Impact factor: 3.507

3.  Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays.

Authors:  A Prakash; T Rezai; B Krastins; D Sarracino; M Athanas; P Russo; M M Ross; H Zhang; Y Tian; V Kulasingam; A P Drabovich; C Smith; I Batruch; L Liotta; E Petricoin; E P Diamandis; D W Chan; M F Lopez
Journal:  J Proteome Res       Date:  2010-11-02       Impact factor: 4.466

Review 4.  The impact of CYP allelic variation on antidepressant metabolism: a review.

Authors:  John L Black; Dennis J O'Kane; David A Mrazek
Journal:  Expert Opin Drug Metab Toxicol       Date:  2007-02       Impact factor: 4.481

5.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma.

Authors:  Terri A Addona; Susan E Abbatiello; Birgit Schilling; Steven J Skates; D R Mani; David M Bunk; Clifford H Spiegelman; Lisa J Zimmerman; Amy-Joan L Ham; Hasmik Keshishian; Steven C Hall; Simon Allen; Ronald K Blackman; Christoph H Borchers; Charles Buck; Helene L Cardasis; Michael P Cusack; Nathan G Dodder; Bradford W Gibson; Jason M Held; Tara Hiltke; Angela Jackson; Eric B Johansen; Christopher R Kinsinger; Jing Li; Mehdi Mesri; Thomas A Neubert; Richard K Niles; Trenton C Pulsipher; David Ransohoff; Henry Rodriguez; Paul A Rudnick; Derek Smith; David L Tabb; Tony J Tegeler; Asokan M Variyath; Lorenzo J Vega-Montoto; Asa Wahlander; Sofia Waldemarson; Mu Wang; Jeffrey R Whiteaker; Lei Zhao; N Leigh Anderson; Susan J Fisher; Daniel C Liebler; Amanda G Paulovich; Fred E Regnier; Paul Tempst; Steven A Carr
Journal:  Nat Biotechnol       Date:  2009-06-28       Impact factor: 54.908

Review 6.  5-HT(3) receptors: potential of individual isoforms for personalised therapy.

Authors:  Beate Niesler
Journal:  Curr Opin Pharmacol       Date:  2011-02-21       Impact factor: 5.547

7.  Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues.

Authors:  Yan Li; Yuan Tian; Taha Rezai; Amol Prakash; Mary F Lopez; Daniel W Chan; Hui Zhang
Journal:  Anal Chem       Date:  2010-12-08       Impact factor: 6.986

Review 8.  Full-length characterization of proteins in human populations.

Authors:  Chad R Borges; Doug S Rehder; Jason W Jarvis; Mathew R Schaab; Paul E Oran; Randall W Nelson
Journal:  Clin Chem       Date:  2009-11-19       Impact factor: 8.327

9.  Mass spectrometric immunoassay.

Authors:  R W Nelson; J R Krone; A L Bieber; P Williams
Journal:  Anal Chem       Date:  1995-04-01       Impact factor: 6.986

Review 10.  Expression and functional proteomics studies in colorectal cancer.

Authors:  Marc A Reymond; Ralf Steinert; Thilo Kähne; Emil Sagynaliev; Abdelkarim S Allal; Hans Lippert
Journal:  Pathol Res Pract       Date:  2004       Impact factor: 3.250

View more
  26 in total

1.  Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring.

Authors:  Akos Végvári; Karin Sjödin; Melinda Rezeli; Johan Malm; Hans Lilja; Thomas Laurell; György Marko-Varga
Journal:  Mol Cell Proteomics       Date:  2013-07-10       Impact factor: 5.911

2.  Evaluating melanoma drug response and therapeutic escape with quantitative proteomics.

Authors:  Vito W Rebecca; Elizabeth Wood; Inna V Fedorenko; Kim H T Paraiso; H Eirik Haarberg; Yi Chen; Yun Xiang; Amod Sarnaik; Geoffrey T Gibney; Vernon K Sondak; John M Koomen; Keiran S M Smalley
Journal:  Mol Cell Proteomics       Date:  2014-04-23       Impact factor: 5.911

3.  An alpha-synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression.

Authors:  Li Yang; Tessandra Stewart; Min Shi; Gwenael Pottiez; Romel Dator; Rui Wu; Patrick Aro; Robert J Schuster; Carmen Ginghina; Catherine Pan; Yuqian Gao; Weijun Qian; Cyrus P Zabetian; Shu-Ching Hu; Joseph F Quinn; Jing Zhang
Journal:  Proteomics Clin Appl       Date:  2017-04-19       Impact factor: 3.494

4.  Molecular biomarkers in glaucoma.

Authors:  Sanjoy K Bhattacharya; Richard K Lee; Franz H Grus
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-07       Impact factor: 4.799

5.  Discovery of a Human Testis-specific Protein Complex TEX101-DPEP3 and Selection of Its Disrupting Antibodies.

Authors:  Christina Schiza; Dimitrios Korbakis; Efstratia Panteleli; Keith Jarvi; Andrei P Drabovich; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2018-08-10       Impact factor: 5.911

Review 6.  Clinical potential of mass spectrometry-based proteogenomics.

Authors:  Bing Zhang; Jeffrey R Whiteaker; Andrew N Hoofnagle; Geoffrey S Baird; Karin D Rodland; Amanda G Paulovich
Journal:  Nat Rev Clin Oncol       Date:  2019-04       Impact factor: 66.675

7.  Targeted proteomic assays for the verification of global proteomics insights.

Authors:  Stefani N Thomas; Hui Zhang
Journal:  Expert Rev Proteomics       Date:  2016-09-01       Impact factor: 3.940

Review 8.  Quality assessment for clinical proteomics.

Authors:  David L Tabb
Journal:  Clin Biochem       Date:  2012-12-12       Impact factor: 3.281

9.  Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues.

Authors:  Jacob J Kennedy; Jeffrey R Whiteaker; Regine M Schoenherr; Ping Yan; Kimberly Allison; Melissa Shipley; Melissa Lerch; Andrew N Hoofnagle; Geoffrey Stuart Baird; Amanda G Paulovich
Journal:  J Proteome Res       Date:  2016-07-27       Impact factor: 4.466

10.  Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.

Authors:  Bryan Krastins; Amol Prakash; David A Sarracino; Dobrin Nedelkov; Eric E Niederkofler; Urban A Kiernan; Randall Nelson; Maryann S Vogelsang; Gouri Vadali; Alejandra Garces; Jennifer N Sutton; Scott Peterman; Gregory Byram; Bruno Darbouret; Joëlle R Pérusse; Nabil G Seidah; Benoit Coulombe; Johan Gobom; Erik Portelius; Josef Pannee; Kaj Blennow; Vathany Kulasingam; Lewis Couchman; Caje Moniz; Mary F Lopez
Journal:  Clin Biochem       Date:  2013-01-08       Impact factor: 3.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.